Modality
Cell Therapy
MOA
GLP-1/GIP
Target
CD19
Pathway
Fibrosis
Ovarian CaBladder CaALS
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
Dec 2017
→ Aug 2028
Phase 1Current
NCT07111960
2,184 pts·Ovarian Ca
2020-01→2025-05·Terminated
NCT06733851
1,759 pts·Ovarian Ca
2017-12→2028-08·Not yet recruiting
3,943 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-05-0611mo agoPh2 Data· Ovarian Ca
2028-08-042.3y awayPh2 Data· Ovarian Ca
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Not yet…
P1/2
Termina…
Catalysts
Ph2 Data
2025-05-06 · 11mo ago
Ovarian Ca
Ph2 Data
2028-08-04 · 2.3y away
Ovarian Ca
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07111960 | Phase 1/2 | Ovarian Ca | Terminated | 2184 | HAM-D |
| NCT06733851 | Phase 1/2 | Ovarian Ca | Not yet recr... | 1759 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 | |
| BEA-4274 | Beam | Phase 1/2 | ALK | |
| VYG-2926 | Voyager | NDA/BLA | CD19 |